Trials / Conditions / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor

Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor

19 registered clinical trials studyying Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor.

Status	Trial	Sponsor	Phase
Terminated	Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervou NCT02255461	Pediatric Brain Tumor Consortium	Phase 1
Withdrawn	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors NCT02194452	Sue O'Dorisio	N/A
Withdrawn	Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue i NCT01795430	City of Hope Medical Center	N/A
Terminated	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spi NCT01076530	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent NCT00994500	National Cancer Institute (NCI)	Phase 1
Completed	ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors NCT00946335	National Cancer Institute (NCI)	Phase 1
Completed	Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagn NCT00638898	City of Hope Medical Center	Phase 1
Completed	Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma NCT00363272	National Cancer Institute (NCI)	Phase 1
Completed	AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors NCT00326664	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, NCT00217412	National Cancer Institute (NCI)	Phase 1
Completed	Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors NCT00100880	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors NCT00077454	National Cancer Institute (NCI)	Phase 1
Completed	Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primit NCT00070525	National Cancer Institute (NCI)	Phase 2
Completed	Cilengitide in Treating Children With Refractory Primary Brain Tumors NCT00063973	National Cancer Institute (NCI)	Phase 1
Completed	Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors NCT00052780	National Cancer Institute (NCI)	Phase 1
Completed	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963	National Cancer Institute (NCI)	Phase 1
Completed	Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas NCT00012181	National Cancer Institute (NCI)	Phase 1